Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:FHTXNASDAQ:OTLKNASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.60+2.0%$1.84$1.29▼$7.85$285.26M1.261.53 million shs2.25 million shsFHTXFoghorn Therapeutics$4.46+8.3%$4.00$2.94▼$10.25$248.61M3.04141,840 shs79,876 shsOTLKOutlook Therapeutics$1.90+1.6%$1.54$0.87▼$9.25$63.78M0.39787,720 shs663,369 shsTVGNTevogen Bio$1.43+1.4%$1.11$0.26▼$3.09$262.97M-0.75.04 million shs685,573 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+1.96%+24.40%+53.85%-5.80%-61.71%FHTXFoghorn Therapeutics+8.25%+7.73%+11.50%-1.33%-28.06%OTLKOutlook Therapeutics+1.60%+2.70%+34.75%+27.52%-73.61%TVGNTevogen Bio+1.42%+11.28%+38.16%+25.44%+82.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon1.3313 of 5 stars3.51.00.00.00.60.80.6FHTXFoghorn Therapeutics2.3639 of 5 stars3.62.00.00.02.51.70.6OTLKOutlook Therapeutics1.8368 of 5 stars3.43.00.00.01.80.00.6TVGNTevogen Bio3.8223 of 5 stars3.54.00.00.02.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50380.77% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13171.86% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$9.60405.26% UpsideTVGNTevogen Bio 3.00Buy$7.10396.50% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, TVGN, ANNX, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/27/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $11.005/12/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/29/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AFHTXFoghorn Therapeutics$23.50M10.58N/AN/A($1.83) per share-2.44OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ATVGNTevogen BioN/AN/AN/AN/A($1.10) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.18N/AN/AN/AN/A-38.99%-33.90%8/11/2025 (Estimated)FHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%8/14/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)TVGNTevogen Bio-$70KN/A0.00∞N/AN/A-396.07%749.97%8/4/2025 (Estimated)Latest OTLK, TVGN, ANNX, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18FHTXFoghorn TherapeuticsN/A4.774.77OTLKOutlook TherapeuticsN/A0.320.64TVGNTevogen BioN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AFHTXFoghorn Therapeutics61.55%OTLKOutlook Therapeutics11.20%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%FHTXFoghorn Therapeutics7.58%OTLKOutlook Therapeutics4.80%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableTVGNTevogen Bio3183.89 million75.97 millionN/AOTLK, TVGN, ANNX, and FHTX HeadlinesRecent News About These Companiestevogen bio expands office lease in new jersey with key amendmentJune 5 at 6:58 PM | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4 at 3:28 AM | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short InterestJune 1, 2025 | marketbeat.comTevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI TechnologiesMay 30, 2025 | quiverquant.comTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Earns Buy Rating from D. Boral CapitalMay 29, 2025 | americanbankingnews.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalMay 28, 2025 | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comTevogen expands target for COVID treatment to seniorsMay 24, 2025 | investing.comTevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...May 24, 2025 | finanznachrichten.deTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23, 2025 | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23, 2025 | globenewswire.comTevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025May 22, 2025 | quiverquant.comTevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual MeetingMay 22, 2025 | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 14, 2025 | marketbeat.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, TVGN, ANNX, and FHTX Company DescriptionsAnnexon NASDAQ:ANNX$2.60 +0.05 (+1.96%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.62 +0.02 (+0.58%) As of 06/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Foghorn Therapeutics NASDAQ:FHTX$4.46 +0.34 (+8.25%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.57 +0.11 (+2.47%) As of 06/6/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Outlook Therapeutics NASDAQ:OTLK$1.90 +0.03 (+1.60%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.89 -0.01 (-0.53%) As of 06/6/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Tevogen Bio NASDAQ:TVGN$1.43 +0.02 (+1.42%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.70%) As of 06/6/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
